Therapeutic Opportunities for Intestinal Angioectasia- Targeting PPARγ and Oxidative Stress

Area of Science:

• Gastroenterology
• Pharmacology
• Genetics

Background:

• Recurrent gastrointestinal bleeding from angioectasia (AEC) poses significant clinical challenges with limited treatment options.
• Understanding AEC pathophysiology is crucial for developing effective therapies.

Purpose of the Study:

• To identify drugs inversely correlated with gastrointestinal bleeding and potentially mitigating AEC severity.
• To explore the underlying molecular mechanisms and genetic pathways involved in AEC.

Main Methods:

• Analysis of 12 million FDA Adverse Event Reporting System (FAERS) reports to identify potential therapeutic agents.
• Validation of FAERS findings using electronic health records (EHRs) from University of Cincinnati Hospital.
• Construction of a gene-regulatory network using murine knockout models and analysis of human colonic tissue and NCBI GEO RNA-Seq data.

Main Results:

• Drugs targeting PPARγ mechanisms and used in diabetes patients were associated with decreased AEC phenotypes.
• EHR data confirmed a 5.6% reduced risk of AEC in patients on PPARγ agonists.
• Gene-regulatory network analysis revealed impacts on wound healing, vasculature development, and oxidative stress regulation in AEC.
• Human AEC tissues showed lower expression of PPARγ and TGFβ1 compared to controls.

Conclusions:

• Integrative analysis reveals altered expression of key genes in oxidative stress and injury repair pathways in AEC.
• This provides novel insights into AEC etiology, paving the way for targeted mechanistic studies.
• Findings support the development of more optimal medical therapies for AEC based on PPARγ agonists and related pathways.